2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 335

Prevalence of Hand Osteoarthritis and Factors Associated with Pain in Korean Farmers

Osteoarthritis - Clinical Aspects Poster I: Treatments and Metabolic Risk Factors

9:00AM-11:00AM: Abstract Number: 841

Prevalence of Systemic Sclerosis in Primary Biliary Cirrhosis Using the New ACR/EULAR Classification Criteria

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 367

Prevention and Treatment of Bone Loss Following Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 621

Previous Diagnosis of Sjögren’s Syndrome As Rheumatoid Arthritis or Systemic Lupus Erythematosus

Sjögren's Syndrome Poster I: Clinical Insights into Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 700

Problems of Untranslatability: Example of Turkish Version of Basdai

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 857

Prognosis Value of Geriatric Assessment Scales in Older Adults with New Onset ANCA-Associated Vasculitis: A Pilot Retrospective Study

Vasculitis Poster I

9:00AM-11:00AM: Abstract Number: 495

Prognostic Significance of Residual Inflammation and Autoantibodies for Disease Relapse upon DMARD Suspension in Patients with Rheumatoid Arthritis in Sustained Remission after DAS-Driven Therapy

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 709

Progression of Patients with Non-Radiographic Axial Spondyloarthritis to Ankylosing Spondylitis: A Population-Based Cohort Study

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 439

Progression of Radiographic Joint Destruction in Patients with Rheumatoid Arthritis Treated with a Biologic Agent in Combination with Methotrexate Versus a Biologic Alone: A Systematic Review and Meta-Analysis of Randomized Trials

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 273

Progression Predictive Factors in Patients with Undifferentiated Connective Tissue Disease: A Cohort Study

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 804

Prolactin Induces Interferon Regulatory Factor 1 Activation and Histone H4 Hyperacetylation in Primary Monocytes Comparable to Changes Seen in Monocytes from Systemic Lupus Erythematosus Patients

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 759

Prolactin Level Is Independently Associated with Circulating CD4+CD28null in Systemic Lupus Erythematosus Patients

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 172

Prospective Assessment of Carotid Intima Media Thickness in Relation to Activity of the Disease in Patients with Rheumatoid Arthritis

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

9:00AM-11:00AM: Abstract Number: 588

Prospective Study about Extension of Dosing Interval with Tocilizumab Therapy in Rheumatoid Arthritis Patients in Remission Maintenance

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 5

Prospective Study of the Effect of Treatment with Adalumumab in Angiogenesis in Moderate or Severe Psoriasis for a Period of 6 Months

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].